FindTrial
Sign In

Ligelizumab

DRUG10 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Allergy, PeanutCholinergic UrticariaChronic Inducible UrticariaChronic Spontaneous UrticariaCold Urticaria

Phase 1

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
TerminatedNCT04513548
Novartis PharmaceuticalsCholinergic Urticaria, Chronic Spontaneous Urticaria, Cold Urticaria
Start: 2020-08-05End: 2022-07-19Updated: 2024-06-18

Phase 2

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
CompletedNCT02649218
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2016-05-24End: 2019-05-02Updated: 2021-10-11
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
CompletedNCT03437278
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2018-08-01End: 2021-02-03Updated: 2026-01-13

Phase 3

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
CompletedNCT03580356
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2018-10-20End: 2022-06-14Updated: 2025-01-07
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
CompletedNCT03580369
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2018-10-17End: 2022-06-14Updated: 2023-07-24
A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines
CompletedNCT03907878
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2019-04-13End: 2022-01-26Updated: 2025-03-06
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
TerminatedNCT04210843
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Start: 2020-04-08End: 2022-09-01Updated: 2024-06-20
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
TerminatedNCT04984876
Novartis PharmaceuticalsAllergy, Peanut
Start: 2021-12-07End: 2023-11-27Updated: 2025-04-29
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
TerminatedNCT05024058
Novartis PharmaceuticalsChronic Inducible Urticaria
Start: 2021-11-16End: 2022-08-09Updated: 2024-06-18

Unknown Phase

Global Managed Access Program Cohort for Ligelizumab in CSU
NCT04903613
Novartis PharmaceuticalsChronic Spontaneous Urticaria
Updated: 2022-05-11

Related Papers

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
2023-11-2338 citations
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis
Pediatric Allergy and Immunology2023-07-0117 citations
Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria
World Allergy Organization Journal2022-11-015 citations
Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria
Clinical and Translational Allergy2022-02-0120 citations
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study
Allergy2021-11-1339 citations
Antibodies to watch in 2020.
2020-01-01328 citations